Researchers at the University of Washington have discovered that a currently FDA-approved drug could help boost the efficacy of immunotherapy against a rare type of liver cancer that has previously been unresponsive to checkpoint inhibitors. The study, focused on fibrolamellar carcinoma, offers new hope for patients with this difficult-to-treat cancer. While this research centered on fibrolamellar carcinoma, other types of cancer are also receiving unprecedented levels of research attention from companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI).
Checkpoint inhibition therapy works by releasing the brakes on the immune system, allowing it to attack cancer cells. However, many cancers, including fibrolamellar carcinoma, have evolved mechanisms to evade this immune response. The University of Washington team found that the approved drug, when combined with checkpoint inhibitors, can re-sensitize cancer cells to immune attack. This breakthrough could transform treatment options for patients with fibrolamellar carcinoma, a disease that primarily affects adolescents and young adults.
The implications of this research extend beyond fibrolamellar carcinoma. The findings suggest that other cancers resistant to immunotherapy might also benefit from this combination approach. The drug's already-approved status could accelerate clinical testing and potential approval for new indications, bypassing some of the lengthy safety trials typically required for novel compounds.
For more information on the latest developments in biotechnology and biomedical sciences, visit BioMedWire. BioMedWire is a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of over 75 brands within the Dynamic Brand Portfolio @IBN that delivers a range of services including access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions.
With a broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the information overload in today’s market, BioMedWire brings its clients unparalleled recognition and brand awareness.
For complete terms of use and disclaimers, please see the BioMedWire website.
